BRIEF-Valeant acquires Canadian rights for Contrave in treatment of obesity

Tue Aug 30, 2016 9:09am EDT
 
Email This Article |
Share This Article
  • Facebook
  • LinkedIn
  • Twitter
| Print This Article
[-] Text [+]

Aug 30 (Reuters) - Valeant Pharmaceuticals International Inc :

* Valeant acquires the Canadian rights for Contrave in the treatment of obesity

* Valeant expects to file with health Canada for regulatory approval by January 2017

* Valeant will be responsible for obtaining Canadian regulatory approval and for all commercialization activities and expenses

* Says Orexigen and Valeant anticipate launching Mysimba in 11 countries in Q4 of 2016

* Orexigen and Valeant anticipate launching Mysimba in 2 countries, in addition to 11 countries, in Q1 of 2017 Source text for Eikon: Further company coverage: